Summary & Overview
HCPCS Level II A2026: Restrata minimatrix, 5 mg
HCPCS Level II code A2026 denotes the supply item “Restrata minimatrix, 5 mg,” used to bill a specific pharmaceutical product in outpatient settings. This code matters nationally because standardized HCPCS reporting enables consistent reimbursement, formulary management, and utilization tracking across payers and care sites. Nationally recognized codes support claims processing, benefit administration, and comparative policy analysis.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for this drug supply item, typical sites of service where it is billed (outpatient clinics, infusion centers, and pharmacies), and what to expect in payer coverage patterns and billing practice. The publication summarizes benchmarks for utilization and reimbursement where available, highlights common billing modifiers and claim considerations, and outlines documentation expectations tied to pharmaceutical supply billing.
This piece is designed to help billing managers, revenue cycle staff, and policy analysts understand how HCPCS Level II code A2026 is used in practice, how major payers approach coverage and claims handling, and where to look for policy updates affecting outpatient drug supply claims.
Billing Code Overview
HCPCS Level II code A2026 describes Restrata minimatrix, 5 mg, a billed supply representing a specific pharmaceutical or drug product formulation. The service type is pharmaceutical supply or drug administration item, and the typical site of service is outpatient clinic, infusion center, or pharmacy-dispensed outpatient setting, where billed drug supplies or drug delivery items are furnished to patients.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with chronic neuropathic pain secondary to diabetic peripheral neuropathy presents for medication management. The clinician prescribes a 5 mg formulation of Restrata minimatrix (A2026) as part of a multimodal pain control plan when prior first-line agents provided inadequate relief. The service is typically dispensed in an outpatient pharmacy or outpatient clinic setting where the medication is administered or supplied to the patient. Clinical workflow: the prescriber documents diagnosis and rationale in the chart, writes the prescription or medication order using the A2026 HCPCS Level II code for billing, pharmacy or clinic staff prepare and dispense the 5 mg minimatrix product, appropriate counseling and medication guides are provided, and documentation of lot number, quantity, and administration or dispensing is recorded in the medical record. Modifiers are appended as needed to indicate unusual circumstances (for example, split/shared services, unusual procedural services, or patient status) for billing with payors including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to dispense or manage medication is substantially greater than typical (e.g., complex counseling, extended medication titration visits). |